HOME >> MEDICINE >> NEWS
Same mortality but higher suicide rate among women with breast implants

Quebec City, September 19, 2006--A study conducted among 24,600 women by two Universit Laval Faculty of Medicine researchers and their colleagues from the Canadian Public Health Agency and Cancer Care Ontario concludes that having breast implants does not increase mortality risk. However, the study reveals that the suicide rate among women with breast implants is 73% higher than in the general population. These findings are published in a recent issue of the American Journal of Epidemiology.

Universit Laval's Jacques Brisson and Louis Latulippe and their colleagues collected information on 17,400 women from the province of Quebec and 7,200 from Ontario who had received breast implants for cosmetic purposes between 1974 and 1989. These women, who had undergone the surgery at an average age of 32, were the subject of regular follow-ups during a 15 year period. A total of 480 women with breast implants died during that period, and cross-referencing with the Canadian Vital Statistic Database was performed to determine the cause of death.

Researchers did not observe any increase in the mortality rate of women with breast implants. In fact, that rate was 26% lower than in the control group. Fewer deaths from cancer--notably breast cancer--and heart disease accounted for most of the discrepancy. The researchers insist that this lower mortality rate is not the result of the breast augmentation procedure itself, but rather of a double selection bias. "First, a woman must be in relatively good health to undergo breast implant surgery," points out Dr. Brisson. "Also, women who receive breast implants tend to be of higher-than-average socioeconomic status. Thus, women who undergo breast augmentation surgery are more likely to be in better health than the general population."

To put this explanation to the test, the research team analyzed a group of 16,000 women who had undergone plastic surgery procedures other than breast augmentation. As in the
'"/>

Contact: Jean-Franois Hupp
jean-francois.huppe@dap.ulaval.ca
418-656-7785
Universit Laval
19-Sep-2006


Page: 1 2

Related medicine news :

1. Trial stops after stroke and mortality significantly reduced by blood
2. Lower mortality rates associated with hospitals that rank highest on quality of care indicators
3. Womens mortality rates for cardiovascular disease differ widely among hospitals
4. Exercise test may help predict mortality risk in heart failure patients
5. Statin use linked with decreased prostate cancer mortality rates, lower PSA levels
6. New study reports improved treatment and reduced mortality for patients with heart failure
7. Change in neuroticism tied to mortality rates, researcher says
8. Annual study finds top hospitals have 28 percent lower mortality rate
9. Hospital performance measures may not make much difference when it comes to mortality
10. Depression, not antidepressants, increases mortality risks in heart failure
11. Systolic blood pressure predicts mortality in heart failure patients

Post Your Comments:
(Date:5/21/2013)... CA (PRWEB) May 21, 2013 Global ... organization, and Bodybuilding.com, the largest online retailer of health ... a new reality-based sports show, Warrior Island. “We ... on; YouTube, Facebook & Twitter, with our unique social ... Island maroons these elite fighters on an island in ...
(Date:5/21/2013)... Boston, Mass.By studying the roles two proteins, thrombospondin-1 ... trans-Atlantic research team has identified a five-amino acid ... in mouse models of prostate, breast and lung ... could potentially block metastasis in a variety of ... Randolph Watnick, PhD, at Boston Children,s Hospital, Vivek ...
(Date:5/21/2013)... or the removal of the adenoids and tonsils, is ... often as a treatment for children with obstructive sleep ... child,s attention and executive functioning, behavior, sleep apnea symptoms, ... until now. A study led by Susan Redline, ... and Cardiovascular Medicine and Associate Clinic Director of the ...
(Date:5/21/2013)... Go Classy Tours, the oldest and ... redesigned their website featuring N Resort in Jamaica ... bars and dining. The website, which has always featured ... guest reviews, will now have a broader range of ... on culinary local recipes, flora and fauna, featured pictures ...
(Date:5/21/2013)... 2013 The American Diabetes Association ( ... the United States of America are affected with peripheral ... great risk of developing peripheral neuropathy which unfortunately makes ... ADA further goes on saying that the disease usually ... 2 million new cases are diagnosed every year in ...
Breaking Medicine News(10 mins):Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 2Health News:Bodybuilding.com Partners with Global Proving Ground’s New Reality Show Warrior Island 3Health News:Changing cancer's environment to halt its spread 2Health News:Changing cancer's environment to halt its spread 3Health News:Early removal of adenoids and tonsils can help pediatric sleep apnea symptoms 2Health News:The Oldest and Original Nudist Travel Agency for NResort Announced Today a Redesigned Website Featuring Information on Culinary Events, Flora and Fauna, and Photography 2Health News:Neuracel Aims to Reduce Peripheral Neuropathy Pain 2
(Date:5/21/2013)... , May 21, 2013  Vasomedical, Inc. (OTC BB: VASO) ... design, manufacture and sale of medical devices and in the ... Jun Ma , President and CEO of ... MicroCap Conference on Thursday, May 30, 2013 in ... The Company,s presentation is scheduled to begin ...
(Date:5/21/2013)... 2013 Reportlinker.com announces that a ... its catalogue:   ... Coherence Tomography (OCT) http://www.reportlinker.com/p01187977/Global-Markets-and-Technologies-for-Optical-Coherence-Tomography-OCT.html#utm_source=prnewswire&utm_medium=pr&utm_campaign=Medical_Imaging ...   BCC,s aim ... synopsis of the current and future characteristics ...
(Date:5/21/2013)... , May 21, 2013  Janssen R&D Ireland ... from the global Phase 3 PROMISE study demonstrating ... (TMC435) led to sustained virologic response 12 weeks ... percent of treatment-experienced genotype 1 chronic hepatitis C ... stages of liver fibrosis, when administered once daily ...
Breaking Medicine Technology:Vasomedical, Inc. To Present At The Second Annual Marcum LLP MicroCap Conference 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 2Global Markets and Technologies for Optical Coherence Tomography (OCT) 3Global Markets and Technologies for Optical Coherence Tomography (OCT) 4Global Markets and Technologies for Optical Coherence Tomography (OCT) 5Global Markets and Technologies for Optical Coherence Tomography (OCT) 6Global Markets and Technologies for Optical Coherence Tomography (OCT) 7Global Markets and Technologies for Optical Coherence Tomography (OCT) 8Global Markets and Technologies for Optical Coherence Tomography (OCT) 9Global Markets and Technologies for Optical Coherence Tomography (OCT) 10Global Markets and Technologies for Optical Coherence Tomography (OCT) 11Global Markets and Technologies for Optical Coherence Tomography (OCT) 12Global Markets and Technologies for Optical Coherence Tomography (OCT) 13Global Markets and Technologies for Optical Coherence Tomography (OCT) 14Global Markets and Technologies for Optical Coherence Tomography (OCT) 15Global Markets and Technologies for Optical Coherence Tomography (OCT) 16Global Markets and Technologies for Optical Coherence Tomography (OCT) 17Global Markets and Technologies for Optical Coherence Tomography (OCT) 18Global Markets and Technologies for Optical Coherence Tomography (OCT) 19Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 2Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 3Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 4Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 5Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 6Primary Efficacy and Safety Findings from Phase 3 Study of Janssen's Simeprevir Administered Once Daily Demonstrate Sustained Virologic Response in Treatment-Experienced Genotype 1 Chronic Hepatitis C Adult Patients 7
Cached News: